B-Cell Chronic Lymphocytic Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
B Cell Chronic Lymphocytic Leukemia Pipeline Drugs Market Overview
B-Cell Chronic Lymphocytic Leukemia pipeline market research report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.
Key Targets in the B-Cell Chronic Lymphocytic Leukemia Pipeline Market
The key targets in the B-Cell Chronic Lymphocytic Leukemia pipeline market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK, CD3, Tyrosine Protein Kinase SYK, Apoptosis Regulator Bcl 2, B Cell Lymphoma 2, B Lymphocyte Antigen CD20, Cells Expressing B Cell Receptor CD22, and Cells Expressing CAMPATH 1 Antigen. Cells Expressing B Lymphocyte Antigen CD19 has the highest number of pipeline products.
B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by Targets
For more target insights, download a free report sample
Types of MoA in the B-Cell Chronic Lymphocytic Leukemia Pipeline Market
The types of key MoA in the B-Cell Chronic Lymphocytic Leukemia pipeline market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK Inhibitor, CD3 Agonist, Tyrosine Protein Kinase SYK Inhibitor, Apoptosis Regulator Bcl 2 Inhibitor, B Cell Lymphoma 2 Inhibitor, B Lymphocyte Antigen CD20 Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, and Cytotoxic To Cells Expressing CAMPATH 1 Antigen. Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19 has the maximum number of pipeline products.
B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by MoA
For more MoA insights, download a free report sample
Types of RoA in the B-Cell Chronic Lymphocytic Leukemia Pipeline Market
The key routes of administration in the B-Cell Chronic Lymphocytic Leukemia pipeline market are intravenous, oral, parenteral, intravenous drip, ophthalmic, subcutaneous, and topical. Intravenous has the majority number of pipeline products.
B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the B-Cell Chronic Lymphocytic Leukemia Pipeline Market
The key molecule types in the B-Cell Chronic Lymphocytic Leukemia pipeline market are gene-modified cell therapy, small molecule, monoclonal antibody, and monoclonal antibody conjugated. Gene-modified cell therapy has the highest number of pipeline products.
B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by Molecule Type
For more molecule type insights, download a free report sample
Key Companies in the B-Cell Chronic Lymphocytic Leukemia Pipeline Market
The key companies in the B Cell Chronic Lymphocytic Leukemia pipeline drugs market are BeiGene Ltd, Bristol-Myers Squibb Co, iDD biotech SAS, Loxo Oncology Inc, AB Science SA, Alexion Pharmaceuticals Inc, and Beijing Immunochina Pharmaceuticals Co Ltd. BeiGene Ltd has the highest number of pipeline products.
AB Science SA: AB Science SA (ABS) is a pharmaceutical company focused on the discovery, development, and commercialization of protein kinase inhibitors. The company’s lead compound Masitinib is an orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, and Lyn in several human indications such as oncology, inflammatory diseases, and central nervous system diseases. AB Science has developed several medicines for humans, ongoing phase 2 and phase 3 studies in oncology and non-oncology diseases. The company is commercializing its lead product candidate in human and veterinary medicine. It has operations in France and the US. ABS is headquartered in Paris, France.
B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
Key targets | Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK, CD3, Tyrosine Protein Kinase SYK, Apoptosis Regulator Bcl 2, B Cell Lymphoma 2, B Lymphocyte Antigen CD20, Cells Expressing B Cell Receptor CD22, and Cells Expressing CAMPATH 1 Antigen |
Key MoA | Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK Inhibitor, CD3 Agonist, Tyrosine Protein Kinase SYK Inhibitor, Apoptosis Regulator Bcl 2 Inhibitor, B Cell Lymphoma 2 Inhibitor, B Lymphocyte Antigen CD20 Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, and Cytotoxic To Cells Expressing CAMPATH 1 Antigen |
Key RoA | Intravenous, Oral, Parenteral, Intravenous Drip, Ophthalmic, Subcutaneous, and Topical |
Key molecule types | Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, and Monoclonal Antibody Conjugated |
Key companies | BeiGene Ltd, Bristol-Myers Squibb Co, iDD biotech SAS, Loxo Oncology Inc, AB Science SA, Alexion Pharmaceuticals Inc, and Beijing Immunochina Pharmaceuticals Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Alexion Pharmaceuticals Inc
BeiGene Ltd
Beijing Immunochina Pharmaceuticals Co Ltd
BioIntegrator
BioInvent International AB
Biosplice Therapeutics Inc
BioXpress Therapeutics SA
Bristol-Myers Squibb Co
Chengdu USino Technology Biology Co Ltd
CRISPR Therapeutics AG
Eisai Co Ltd
Hangzhou Hezheng Pharmaceutical Co Ltd
iDD biotech SAS
Kuur Therapeutics Ltd
Loxo Oncology Inc
Mediolanum farmaceutici SpA
Merck & Co Inc
Nkarta Inc
Nordic Nanovector ASA
Regeneron Pharmaceuticals Inc
Shanghai Pharmaceutical Group Co Ltd
Tianweiyuan and Biomedicine Shanghai Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the B-Cell Chronic Lymphocytic Leukemia pipeline market?
The key targets in the B-Cell Chronic Lymphocytic Leukemia pipeline market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK, CD3, Tyrosine Protein Kinase SYK, Apoptosis Regulator Bcl 2, B Cell Lymphoma 2, B Lymphocyte Antigen CD20, Cells Expressing B Cell Receptor CD22, and Cells Expressing CAMPATH 1 Antigen.
-
What are the types of MoA in the B-Cell Chronic Lymphocytic Leukemia pipeline market?
The types of key MoA in the B-Cell Chronic Lymphocytic Leukemia pipeline market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK Inhibitor, CD3 Agonist, Tyrosine Protein Kinase SYK Inhibitor, Apoptosis Regulator Bcl 2 Inhibitor, B Cell Lymphoma 2 Inhibitor, B Lymphocyte Antigen CD20 Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, and Cytotoxic To Cells Expressing CAMPATH 1 Antigen.
-
What are the types of RoA in the B-Cell Chronic Lymphocytic Leukemia pipeline market?
The key routes of administration in the B-Cell Chronic Lymphocytic Leukemia pipeline market are intravenous, oral, parenteral, intravenous drip, ophthalmic, subcutaneous, and topical.
-
What are the key molecule types in the B-Cell Chronic Lymphocytic Leukemia pipeline market?
The key molecule types in the B-Cell Chronic Lymphocytic Leukemia pipeline market are gene-modified cell therapy, small molecule, monoclonal antibody, and monoclonal antibody conjugated.
-
What are the key companies in the B-Cell Chronic Lymphocytic Leukemia pipeline market?
In the B-Cell Chronic Lymphocytic Leukemia pipeline market, the key companies are BeiGene Ltd, Bristol-Myers Squibb Co, iDD biotech SAS, Loxo Oncology Inc, AB Science SA, Alexion Pharmaceuticals Inc, and Beijing Immunochina Pharmaceuticals Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.